In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Selected Start-Ups (11/04)

Executive Summary

In Vivo briefly summarizes the technologies of these recently founded companies: Cynexus, Nitec Pharma, PanOpsys, QRG Bioscience, RiboNovix and SensiGen.

You may also be interested in...



FDA Revokes Second COVID-19 Diagnostic EUA Over Performance Concerns

Autobio’s test reportedly only correctly identified half the positive COVID-19 samples in an NIH evaluation.

US GAO Review Of FDA’s OTC Drug Oversight Signals Waiting For Monograph Reform Benefits

Benefits of OTC monograph reform legislation passed in March likely will take at least several years, according to GAO report to Congress. It notes the FDA still is analyzing the legislation and it may need two years to add and train staff.

Internal US FDA Disagreements Feature In One-Quarter Of Novel Approvals

A team led by Dalhousie University researchers examined 174 novel approvals from 2011-2015 and found 155 instances of disagreement, affecting 42 drugs.

Related Companies

UsernamePublicRestriction

Register

SC141576

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel